📰 Wilson Wolf News
Wilson Wolf News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Wilson Wolf. Real-time updates on events, politics, business and more.
May 29, 2024
St. Paul, MN, May 29, 2024 – ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene-modified cell therapies (CGT). The G-Rex® Gran...
May 2, 2024
Bio-Techne Corporation beats earnings expectations. Reported EPS is $0.48, expectations were $0.46.
May 1, 2024
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024...
February 2, 2024
The first four inductees will be honored at tonight's boys varsity basketball game.
February 1, 2024
MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation today reported its financial results for the second quarter ended December 31, 2023. Second Quarter FY2024 Highlights Second quarter...
January 4, 2024
MINNEAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Bio-Techne Corporation today announced it will present its portfolio of products and solutions to enable cell and gene therapy development and...
November 1, 2023
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2024.
October 31, 2023
MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation today reported its financial results for the first quarter ended September 30, 2023. First Quarter FY2024 Highlights First quarter...
September 28, 2023
At Advanced Therapies Europe 2023, BioPharma Reporter caught up with ScaleReady's Jenny Stjernberg to discuss her work at the biotech company, her journey from academia to commercial and female representation in the cell and gene therapies industry.
September 27, 2023
At Advanced Therapies Europe 2023, BioPharma Reporter caught up with ScaleReady's Jenny Stjernberg to discuss her work at the biotech company, her journey from academia to commercial and female representation in the cell and gene therapies industry.